Hook & thesis
Hims & Hers (HIMS) just went through a volatile earnings cycle. Q1 results on 05/15/2026 stopped the market's short-term momentum — revenue grew, but margins and adjusted EBITDA took a hit as the company pivots from compounded GLP-1s to reselling branded products. That pivot is the point: the near-term drama is largely transitory and driven by product mix and advertising changes, while the business still has structural growth levers in telehealth, weight-loss, hair and skincare. I think the market has overreacted to one quarter of margin compression. The path back to normalized margins and renewed subscriber momentum supports a swing trade into HIMS.
My trade idea is to take a long, mid-term swing position: buy HIMS at $25.05, set a stop loss at $21.00 to cap downside, and target $32.00 within a 45-trading-day horizon. That plan balances current momentum with the known risks around margin recovery and execution on the Novo Nordisk partnership.
What Hims & Hers does and why the market should care
Hims & Hers operates a consumer-facing telehealth and e-commerce platform connecting patients to clinicians and medications across mental health, sexual health, dermatology, primary care and now branded weight-loss therapeutics. The shift matters because weight-loss drugs - particularly GLP-1s - are large, sticky, and high-frequency market opportunities. HIMS's settlement with Novo Nordisk gave it the right to sell brand-name Wegovy and Ozempic on its platform and stopped advertising compounded alternatives. That materially changes unit economics and regulatory exposure.
Recent facts and why they matter
- Revenue momentum: Q1 revenue was $608.1 million (reported 05/15/2026), up 4% year-over-year and management raised full-year revenue guidance to $2.8-3.0 billion. That signals the top line is still growing despite the strategic reset.
- Profitability pressure: the company swung to a $92.1 million net loss in Q1 from a $49.5 million profit a year earlier. Adjusted EBITDA fell roughly 51% year-over-year and gross margins compressed from 73% to 65% as the product mix shifted toward lower-margin branded drugs and the company increased investment internationally and in AI/diagnostics.
- GLP-1 traction: HIMS fulfilled over 125,000 Wegovy shipments in early rollout — meaningful evidence the distribution deal is working at a consumer level even though unit economics differ from compounded prescriptions.
- Valuation and capital structure: the market values HIMS at roughly $5.7 billion today (market cap ~ $5.71B) with a price-to-sales of 2.45 and enterprise value of ~ $6.55B. Free cash flow was reported at ~$66.9 million, EV/sales sits at ~2.76, and the balance sheet shows leverage with a debt-to-equity ratio of 2.18.
- Market technicals and sentiment: HIMS currently trades at $25.05. Short interest has been meaningful through the year (for example, 63.16 million shares short as of 04/30/2026), but days-to-cover metrics have shortened recently. The 10- and 20-day SMAs sit above and around current price levels, signalling mixed technicals.
Valuation framing
At ~ $25 a share and a market cap near $5.7 billion, HIMS is priced like a growth business that must deliver higher subscriber growth and/or margin expansion to justify multiples. The stock's price-to-sales of 2.45 is not cheap relative to early-stage healthcare growth peers but reasonable if HIMS reclaims higher gross margins and drives cross-sell economics from diagnostics and recurring prescriptions. The immediate valuation gap is driven by compressed adjusted EBITDA guidance (management lowered adjusted EBITDA expectations to $275-350 million for 2026) and investor uncertainty about the long-term margin profile of a branded GLP-1 resale model versus the old compounded model.
Trade plan (actionable)
Entry: Buy HIMS at $25.05 (market).
Stop loss: $21.00.
Target: $32.00.
Time horizon: mid term (45 trading days). I expect this trade to play out over roughly 45 trading days because the post-earnings sell-off already priced in immediate fear; the next two months should reveal whether volumes and margins stabilize as the Wegovy program scales and marketing normalizes.
Why these levels? $25.05 is the current market price and offers immediate exposure to any stabilization or positive sentiment. The stop at $21.00 limits downside to roughly 16% from entry and acknowledges the possibility that margin deterioration or an adverse regulatory development could prolong the sell-off. The $32.00 target — about 28% upside — prizes a scenario where revenue guidance is upheld, gross margins begin to recover from 65% back toward historical levels, and Wall Street revisits forward adjusted EBITDA assumptions.
Catalysts to drive the trade
- Margin stabilization: evidence over the next several quarters that gross margins stop deteriorating and adjusted EBITDA guidance holds closer to the top end of the $275-350 million range.
- Wegovy/Ozempic scale: continued month-to-month shipment growth beyond the reported 125,000 units, signifying consumer demand and platform execution.
- Subscriber growth: renewed acceleration in subscribers toward management targets (management was targeting subscriber counts above 2.5 million in prior commentary), which would support recurring revenue multiples.
- Positive macro tailwinds for consumer healthcare: any easing in rate-cut expectations or broader risk-on market flows could lift growth-healthcare stocks that have been oversold.
Risks and counterarguments
- Margin-risk persists: The company explicitly called out gross margin compression from 73% to 65% in Q1. If branded GLP-1 resale proves structurally lower-margin than management expects, adjusted EBITDA and free cash flow upside will be limited and the stock could re-test 2026 lows.
- Competition and reimbursement: Branded GLP-1s are subject to competitive pricing pressure and payer negotiation. Changes in reimbursement or wider access policies could reduce consumer uptake and push patients to other channels.
- Execution risk on international and diagnostic initiatives: Management is increasing investments in international expansion, AI and diagnostics. These are positive long-term moves but increase near-term spend and execution complexity — exactly what investors punished in the recent quarter.
- Macro and rate environment: Repricing of rate-cut odds and higher yields creates headwinds for growth equities. HIMS has a leveraged capital structure (debt-to-equity ~2.18), so a weaker equity backdrop could depress valuation multiples even if fundamentals stabilize.
- Counterargument: A plausible bear case is that the Novo Nordisk settlement simply converted one regulatory risk into another — dependence on the economics of selling branded GLP-1s. If margins settle materially lower and subscriber growth falters, the company could shrink toward a lower-growth telehealth multiple, and the stock would remain pressured. This is a real possibility and the trade incorporates it via a tight stop.
What would change my mind
I would abandon this long swing if any of the following occur: (a) management provides updated guidance or commentary implying full-year revenue guidance below $2.8 billion or pushes adjusted EBITDA guidance materially below $275 million; (b) trends in Wegovy shipments plateau or reverse from an already healthy initial tally of 125,000; (c) gross margins continue to compress rather than stabilize; or (d) a near-term adverse regulatory decision limits resale or distribution of branded GLP-1 therapies.
Quick reference table
| Metric | Value |
|---|---|
| Current price | $25.05 |
| Q1 Revenue | $608.1M (05/15/2026) |
| Q1 Net | $-92.1M |
| Full-year revenue guide | $2.8 - $3.0B |
| Gross margin (Q1) | 65% (compared with 73% prior) |
| Market cap | $5.7B |
| EV | $6.55B |
| Price-to-sales | 2.45 |
Bottom line
HIMS is a classic post-earnings trade: the market punished a transition quarter, but the underlying revenue growth and early Wegovy distribution figures offer a credible path back to normalized margins and growth. This is not a low-risk play - the company lowered near-term profitability expectations and faces execution risks on new initiatives - but with disciplined risk control (stop at $21.00) and a 45-trading-day horizon, the reward-to-risk profile looks attractive. If you believe branded GLP-1 distribution can scale and management can stabilize margins, HIMS offers an asymmetric mid-term opportunity.
Key signals to watch while holding the trade
- Weekly channel and unit shipment updates for Wegovy/Ozempic.
- Gross-margin commentary and adjusted EBITDA trajectory in any corporate updates or the next quarterly report.
- Subscriber trends and ARPU metrics showing whether higher-frequency drug categories are driving stickiness.
Trade plan recap: Buy at $25.05, target $32.00 within 45 trading days, stop at $21.00. Stay nimble; this is a high-conviction swing conditioned on margin stabilization and continued GLP-1 demand.